Please login to the form below
New medical animation company launched
Fusion Medical Animation, a new company specialising in drug mode of action (MOA) animation has been founded by Simon Reid, the former director of production at Random42
Fusion Medical Animation, a new company specialising in drug mode of action (MOA) animation for the pharma, research and healthcare industries has been founded by Simon Reid, the former director of production at Random42.
MOA animations communicate the biochemical interaction through which a drug substance produces its pharmacological effect. Targeted at physicians, Fusion's animations can lead to greater awareness and adoption of clients' products.
With photo-real animation now common place in film, television and increasingly online, pharma clients are beginning to expect this sort of quality animation and CGI, to explain and market their new drugs and products.
An example of Fusion's MOA animation
Fusion's unique position allows them to combine feature film quality graphics, along with scientifically accurate pharmaceutical MOA expertise.
Before moving to the pharmaceutical industry as director of production at a leading MOA animation agency, Reid spent many years setting up and running various visual effects departments for factual broadcast.
In addition to their work in the pharmaceutical arena, Fusion has worked on the landmark BBC science series "First Life" presented by Sir David Attenborough as well as producing the medical/science shots for another Attenborough documentary, "Flying Monsters", a stereoscopic production for the new Sky 3D channel and IMAX theatres.
Share
Related Hub content
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
